| pubmed-article:3058137 | pubmed:abstractText | Treatment with the selectively immunomodulatory drug 1-[2-methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridine-carbonitrile (ciamexon, BM-42332), an aziridine derivative, of newly diagnosed type I diabetic patients is reported. In an open pilot study the treatment of Cx led to the independence of insulin in 33.3% of the treated patients. | lld:pubmed |
